Inhibikase Therapeutics, Inc. (IKT) vs X4 Pharmaceuticals, Inc. (XFOR)
Inhibikase Therapeutics, Inc. and X4 Pharmaceuticals, Inc. are both Biotechnology companies. Inhibikase Therapeutics, Inc. and X4 Pharmaceuticals, Inc. are of similar size ($297.4M and $293.0M). Inhibikase Therapeutics, Inc. grew revenue faster over the last twelve months: 110.9% against −51.7%. Inhibikase Therapeutics, Inc. has the higher net margin (0.00% vs −568.8%) and the higher return on invested capital (0.00% vs −226.6%). Across the 17 metrics below, Inhibikase Therapeutics, Inc. leads on 12 and X4 Pharmaceuticals, Inc. on 5.
Valuation
Profitability
| Metric | IKT | XFOR | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 81.51% | 65.16% |
| Operating margin | 0.00% | (554.71%) | 0.00% |
| Net margin | 0.00% | (568.80%) | 0.00% |
| Free cash flow margin | 0.00% | (559.95%) | 0.00% |
| Return on equity | (51.96%) | (113.08%) | (57.72%) |
| Return on assets | (48.04%) | (50.32%) | (49.22%) |
| Return on invested capital | 0.00% | (226.62%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack